Fraxiparine

PreclinicalSmall molecule

LLeiden University Medical Center

Fraxiparine is one of 33 small molecule programs targeting Prevention. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PreventionCompleted

PreventionPreclinical

Completed

Competition

Competitive Landscape

38 competitors in Prevention

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

8 2

Prograf

VVeloxis Pharmaceuticals

Phase 3

4 3

Orencia

Bristol-Myers Squibb

Phase 2

2 4

Ilaris

Novartis

Phase 2

1 5

Cytoxan

BBaxter Healthcare Corporation

Phase 2

6 6

BCG Vaccine

GGynecologic Oncology Group

Phase 3

1 7

Epsom Salt

FFresenius Kabi USA, LLC

Phase 2

1 8

Didronel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 9

CPX-351

Jazz Pharmaceuticals

Phase 2

1 10

Interferon Gamma 1-B

AAssistance Publique - Hôpitaux de Paris

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prevention1 trial

Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events

Completed·LLeiden University Medical Center·N/A·NCT02987946·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fraxiparine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fraxiparine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fraxiparine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leiden University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLeiden University Medical Center

Fraxiparine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prevention1 trial

References

Drug Info

Quick Facts

Related News